Key information

Recruitment dates:

26 May, 2017 to 1 September, 2020
(Trial recruitment open)

Trial investigator:

Andrew Clamp  0161 446 3606    Andrew.Clamp@christie.nhs.uk   

Acronym:

MOLTO

Clinical trial locations

Location list

Contact: The Christie NHS Foundation Trust
Address:
Manchester
M20 4BX
Tel: 0161 446 3606

About the trial

PARP inhibitors, such as olaparib, significantly improve progression free survival (PFS) in participants with recurrent, platinum-sensitive high-grade serous/endometrioid ovarian cancer (HGS/EOC), who have a mutation in BRCA 1 or 2 genes.  The investigators will test the feasibility of administering a second course of olaparib in participants who have recurrent platinum-sensitive HGS/EOC.

 

Who can take part?

For women with a recurrence of measureable high grade serous or endometrioid ovarian cancer, fallopian tube or primary peritoneal cancer

Participants who have not been treated with PARP inhibitor previously will be treated with two maintenance courses of olaparib.
Participants, who have received one course of maintenance olaparib before entry to the trial, will only receive one further course of treatment.

Aged 18 or over.

Other criteria will also apply as described by the medical team.

Further information: https://clinicaltrials.gov/ct2/show/study/NCT02855697#contacts

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.